Key Features of the SLiME Platform

·No animal immunization required → enabling faster and more ethical antibody development
·AI-driven synthetic libraries designed through advanced structure prediction
·Phage libraries for high-throughput screening and selection of diverse candidates
·Achieving antigen-binding affinity at the nano- to picomolar level
·Extensive library diversity, allowing broad target coverage
·Ccombody offers superior scalability, design flexibility, and environmental stability compared to conventional IgG and nanobodies
·Optimized for large-scale production using Gram-positive expression systems, suitable for industrial applications
·Applicable to the development of various biomaterials, including diagnostics, therapeutics, and veterinary products
·Positioned as a next-generation AI-integrated antibody platform with wide applicability across research and industry